Lutropin alfa is a form of recombinant human luteinizing hormone used to treat female infertility due to hypothalamic or pituitary insufficiency, or due to profound luteinizing hormone deficiency. Lutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues.
- Mechanism
- Curator reviewed
Luteinizing hormone binds to a receptor shared with the human chorionic gonadotropin hormone (hCG) on the ovarian theca (and granulosa) cells and testicular Leydig cells. This LH/CG transmembrane receptor is a member of the super-family of G protein-coupled receptors. Adenylate cyclase then activates many other pathways leading to steroid hormone production and other follicle maturation processes.
- Primary indication
- For treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency (LH <1.2 international units [IU]/L)Curator reviewed · 2 structured indications
- Formula / weight
- C1014H1609N287O294S27 · 30000.0 Da
- First approval
- Canada, 2005 · United States, 2004 · European Union, 2016
- Also known as
- Lutropin alpha · Recombinant LH · rLH
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Lutropin alfa, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account